**AOXIN Q & M DENTAL GROUP LIMITED**
(Company Registration Number: 201110784M)
(Incorporated in the Republic of Singapore)

---

**UPDATE FROM ACUMEN DIAGNOSTICS PTE. LTD.**

**EXPIRY OF CLINICAL LABORATORY SERVICE LICENCE**

---

The board of directors (the "**Board**" or "**Directors**") of Aoxin Q & M Dental Group Limited (the "**Company**", and collectively with its subsidiaries, the "**Group**") wishes to refer to the announcement dated 29 June 2024 ("**29 June Announcement**") and update that Acumen Diagnostics Pte. Ltd. ("**Acumen**"), an associated company of the Company, was notified on 13 September 2024 by the Ministry of Health ("**MOH**") that the clinical laboratory service licence ("**Laboratory Licence**") issued by MOH to Dr Ong Siew Hwa ("**Dr Ong"**) as the licensee, provided under the business name of Acumen, will expire on 15 September 2024. By way of background, Acumen had taken steps to change the Principal Officer from Dr Ong to Mr Lua Chong Hui Joseph and licensee of the Laboratory Licence to Acumen. MOH stated in its letter, amongst other things, that:

(a) the application to change the Principal Officer from Dr Ong to Mr Lua Chong Hui Joseph will be rejected, as the application was not submitted by or on behalf of the licensee of the Laboratory Licence, Dr Ong; and

(b) the request to change the licensee of the Laboratory Licence from Dr Ong to Acumen will also be rejected, as the Laboratory Licence does not allow for the transfer or assignment of such licence.

The Letter stated that if Acumen intends to provide clinical laboratory service, it should apply for a new Laboratory Licence.

Accordingly, Acumen has temporarily ceased one of its business and operations related to the Laboratory Licence with effect from 15 September 2024. The board of directors of Acumen is considering the next steps to be taken, including but not limited to applying to the MOH for a new Laboratory Licence. Depending on the future plans that Acumen's board of directors have for Acumen's business, the Board will assess and review the consequential financial impact on the earnings per share and net tangible assets per share of the Group for the current financial year ending 31 December 2024.

As stated on the 29 June Announcement, the board of directors of Acumen had placed Dr Ong on leave of absence (which is disputed by her). A copy of the said announcement can be found on the website of the Singapore Exchange Securities Trading Limited at https://www.sgx.com/securities/company-announcements.

The Company will make further announcement(s) to keep shareholders updated as and when there are material developments to the matter. **Shareholders are advised to exercise caution when dealing in the securities of the Company and to refrain from taking any action in relation to their shares which may be prejudicial to their interests.**

**By Order of the Board**

Mr. Chua Ser Miang
Non-Executive Chairman and Independent Director

16 September 2024

---

For more information, please contact:
**Financial Controller**
Loo Keat Choon
Tel: 6235 1188
Email: calvin@aoxin.sg

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg*